Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on behalf of The American Society of Transplantation and Cellular Therapy and the European Society of Blood and Marrow Transplantation

•Autologous-HCT is recommended as an option for consolidation therapy in patients with progression of disease within 24 months of receiving front line chemoimmunotherapy and who do not have evidence of histological transformation and achieve a CR or PR to salvage second line therapy.•CAR-T should be considered a treatment option for patients who do not achieve CR or PR after second or subsequent lines of therapy.•Allogeneic-HCT can be considered as consolidative treatment in select cases of relapsed chemosensitive FL patients who have received 3 or more lines of systemic therapy and are in the following clinical scenarios: post CAR-T failure; lack of access to CAR-T; concomitant therapy related myeloid neoplasm or bone marrow failure syndrome.